Inactive Instrument

Analyst Reco. Clarus Therapeutics Holdings, Inc.

Equities

Needham & Co Downgrades Clarus Therapeutics to Hold From Buy	22/22/22	MT
Maxim Downgrades Clarus Therapeutics Holdings to Hold From Buy	22/22/22	MT
Truist Securities Adjusts Clarus Therapeutics Holdings' Price Target to $3 from $7, Keeps Buy Rating	17/22/17	MT
Needham & Co. Adjusts Price Target for Clarus Therapeutics to $3 From $8, Reiterates Buy Rating	17/22/17	MT
Needham Lowers Clarus Therapeutics Holdings Price Target to $8 From $12, Maintains Buy Rating	31/22/31	MT
Cantor Fitzgerald Adjusts Clarus Therapeutics Holdings Piece Target to $3 From $20, Maintains Overweight Rating	31/22/31	MT
Oppenheimer Adjusts Price Target on Clarus Therapeutics Holdings to $14 From $12, Maintains Outperform Rating	24/21/24	MT
CLARUS THERAPEUTICS : Truist Securities Starts Clarus Therapeutics Holdings at Buy with $10 Price Target	13/21/13	MT
CLARUS THERAPEUTICS : Needham Starts Clarus at Buy With $12 Price Target	06/21/06	MT
CLARUS THERAPEUTICS : Maxim Group Initiates Clarus Therapeutics Hldgs at Buy Rating With $13 Price Target	29/21/29	MT
CLARUS THERAPEUTICS : Oppenheimer Initiates Coverage on Clarus Therapeutics Holdings With Outperform Rating, $12 Price Target	20/21/20	MT
CLARUS THERAPEUTICS : Cantor Fitzgerald Starts Clarus Therapeutics at Overweight With $20 Price Target	20/21/20	MT

No results for this search